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Abstract 
Inhibition of extracellular matrix (ECM) degradation may represent a mechanism for cardiac 
protection against ischemia. Extracellular matrix metalloproteinase inducer (EMMPRIN) is highly 
expressed in response to acute myocardial infarction (AMI), and induces activation of several 
matrix metalloproteinases (MMPs), including gelatinases MMP-2 and MMP-9. We targeted 
EMMPRIN with paramagnetic/fluorescent micellar nanoparticles conjugated with the EMMPRIN 
binding peptide AP-9 (NAP9), or an AP-9 scrambled peptide as a negative control (NAPSC). We 
found that NAP9 binds to endogenous EMMPRIN in cultured HL1 myocytes and in mouse hearts 
subjected to ischemia/reperfusion (IR). Injection of NAP9 at the time of or one day after IR, was 
enough to reduce progression of myocardial cell death when compared to Control and NAPSC 
injected mice (infarct size in NAP9 injected mice: 32%±6.59 vs Control: 46%±9.04 or NAPSC 
injected mice: 48%±7.64). In the same way, cardiac parameters were recovered to almost healthy 
levels (LVEF NAP9 63% ± 7.24 vs Control 42% ± 4.74 or NAPSC 39% ± 6.44), whereas ECM 
degradation was also reduced as shown by inhibition of MMP-2 and MMP-9 activation. Cardiac 
magnetic resonance (CMR) scans have shown a signal enhancement in the left ventricle of NAP9 
injected mice with respect to non-injected, and to mice injected with NAPSC. A positive corre-
lation between CMR enhancement and Evans-Blue/TTC staining of infarct size was calculated 
(R:0.65). Taken together, these results point to EMMPRIN targeted nanoparticles as a new ap-
proach to the mitigation of ischemic/reperfusion injury. 
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Introduction 
Early coronary artery reperfusion is the most ef-
fective procedure for the treatment of acute myocar-
dial infarction (AMI)1. However, reperfusion associ-
ated damage often worsens cardiac integrity, in part 
by eliciting an extensive inflammatory response in 
which proinflammatory macrophages play a pivotal 
role through the expression of extensive amounts of 
proinflammatory cytokines and extracellular matrix 
metalloproteinases (MMPs), thus contributing to 
ventricular injury2-3. 
MMPs are proteolytic degrading enzymes that 
cleave several proteins, including extracellular matrix 
components. In the heart, MMP activation induces 
cardiac myocyte necrosis and heart failure, and elicits 
abnormal ventricular remodeling 4. In this regard, the 
extracellular matrix metalloproteinase inducer 
EMMPRIN (CD147) regulates the expression of sev-
eral MMPs and plays a role in the inflammatory re-
sponse to ischemia in monocytes and cardiac cells 5. 








highly expressed in monocytes and cardiac myocytes 
in response to AMI 6, and promotes the expression 
and activity of several MMPs, including MMP-2, 
MMP-9, MT1-MMP, and MMP-137.  
We hypothesized that targeted inhibition of 
EMMPRIN may represent a new mechanism of car-
diac protection, by preventing ECM degradation and 
myocyte cell death, thereby preserving heart contrac-
tility following ischemic reperfusion.  
Materials and Methods 
Reagents 
General cell culture supplies were purchased 
from BD Biosciences (Spain); calf serum was from 
BioWhittaker (Verviers, Belgium). Cell culture-grade 
gelatin, trypsin, antibiotics, hematoxylin-eosin, Tri-
chrome Masson staining reagents, Evans blue, and 
TTC dyes were from Sigma (Spain). HRP-conjugated 
anti-mouse secondary antibody and liquid DAB sub-
strate were from Dako (Carpinteria, CA). An-
ti-MMP-2, MMP-9, CD68, and FITC-conjugated sec-
ondary antibodies were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Anti-heavy chain cardiac myo-
sin antibody was from Abcam (Abcam, UK). 
HRP-conjugated anti-rabbit secondary antibody was 
from Sigma-Aldrich. Amersham ECL detection kit 
was from GE (GE Healthcare Life Sciences, Spain). 
Centrifugation concentrators were from Sartorius 
(Fischer Scientific, Spain). 
Cells 
The HL1 cardiomyocyte cell line was kindly 
donated by Dr. Antonio Bernad. 
Animals  
Wild type C57BL/6 mice were purchased from 
Charles River, and housed in our animal facilities in 
isolated rooms. All animal procedures were approved 
by the National Research Ethics Committee and con-
formed to EU Directive 86/609/EEC and recommen-
dation 2007/526/EC regarding the protection of ani-
mals used for experimental and other scientific pur-
poses (enacted under Spanish law 1201/2005).  
Animal model of Ischemia/Reperfusion  
Ischemia was induced by coronary artery liga-
tion. Twelve-week-old mice were intraperitoneally 
anesthetized with ketamine/xylazine (100 and 10 
mg/kg, respectively), intubated with a 1-mm steel 
tube, and ventilated (2ml, 80 strokes/min). The thorax 
was opened between the second and the third ribs 
and widened with the aid of a mouse retractor. The 
pericardium was opened and LAD was occluded for 
30 min close to its bifurcation by using a 6-0 silk su-
ture. Blanching of the ventricle provided direct evi-
dence of coronary occlusion. Reperfusion was per-
formed by ligation release. After the procedure, the 
chest was closed, negative pressure restored, and the 
skin sutured. Control mice (sham) were included in 
the assays, in which the same procedure was per-
formed except for occlusion of the left coronary artery. 
Determination of infarct size 
Myocardial infarct size was determined by dou-
ble staining with Evans Blue/TTC dyes. Animals 
were anesthetized and a 0.2% Evans Blue solution was 
injected into the aorta, allowing for uniform distribu-
tion of the dye. Animals were sacrificed, the hearts 
frozen, sliced in 1mm ring sections perpendicular to 
the LV long axis, and incubated with 0.5% TTC solu-
tion for 5 minutes. Healthy tissue (blue), area at risk 
(red), and infarct tissue (pale white) areas were sub-
jected to morphometric analysis by using the Motic 
Images Plus software. 
Echocardiography 
Mouse hearts were visualized by echocardiog-
raphy over time, using a high-frequency mi-
cro-ultrasound system (Vevo 2100; VisualSonics, To-
ronto, ON, Canada). Mice were anesthetized with 
1.5% isoflurane gas, resulting in a heart rate of ap-
proximately 400 beats/min. Anesthetized animals 
were placed on the Integrated Rail System and Mouse 
Handling Table (provided by the manufacturer), 
which allows simultaneous acquisition of tempera-
ture data (37°C, by using the integrated heating pad) 
and electrocardiography (lead II) throughout the ex-
periment. The chest of the mouse was carefully 
shaved, and warm ultrasound transmission gel was 
applied to ensure optimal image quality. Parasternal 
short-axis-view images of the heart were recorded 
using a 30-MHz RMV scan head in a B-mode to allow 
M-mode recordings by positioning the cursor in the 
parasternal short-axis view perpendicular to the in-
terventricular septum and posterior wall of the left 
ventricle. From these recordings, the following pa-
rameters were determined using the on-site software 
cardiac package (Visual Sonics): left-ventricle 
end-diastolic diameter, left-ventricle end-diastolic 
volume, ejection fraction, and shortening fraction. 
Histology and immunohistochemistry 
Histological and immunohistochemical proce-
dures were performed as previously described 7. In 
brief, mouse hearts were embedded in paraffin and 
10, 4-µm serial sections (300 µm apart) were obtained 
from the apex to the mid LAD coronary artery. Im-
munohistochemical detection of EMMPRIN was per-
formed by incubating sections with the corresponding 
primary and secondary antibodies. Red fluorescence 




emitted by NAP9 and NAPSC was detected at 600 nm 
wave-length in a Leica TCS SP5 II confocal micro-
scope. Red and green intensities from each serial sec-
tion (8-10 slides/section) were analyzed with the 
“co-localization finder” plugin NIH Image J64 soft-
ware. 
Flow cytometry 
The effect of NAP9 and NAPSC on cell viability 
was determined by flow cytometry (FACS scanner, 
Becton Dickinson) using propidium iodide (RD sys-
tems) and annexin V conjugates (Life Technologies), 
as provided by the manufacturers.  
Immunoblot analysis 
Isolation of protein lysates and immunoblots 
were performed as described 7.  
Peptide and Nanoprobe composition 
Peptide AP9: YKLPGHHHHYRP.  
Peptide AP9-scrambled: HYJLPGHRHPYHK.  
The paramagnetic nanoparticles were prepared 
by the lipid film hydration method, with modifica-
tions as described 15. In brief, a film was prepared by 
rotary evaporation of Gd-DTPA-bis (GdDTPA-BSA), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[
methoxy (polyethylene glycol)-2000] 
(DSPE-PEG2000), DSPE-PEG2000-maleimide, and 
Rhodamine-PE, in a molar ratio 
50:39:1:10, dissolved in a mix-
ture of chloroform/methanol 
(4:1 v/v). The lipid film was 
hydrated with HEPES buffer, 
pH 6.7, and 150 mM NaCl, and 
the solution was rotated at 65°C 
for 1 hour. AP9 and the corre-
sponding scrambled peptides 
were modified by adding a ter-
minal cysteine residue (Fig. 1) to 
bind to the maleimide moiety at 
a molar ratio 1:40 (mi-
celle:peptide). Uncoupled pep-
tides were separated with cen-
trifuge concentrators of 100 kDa. 
The number of peptide mole-
cules bound per micelle was 
calculated by HLPC, estimating 
4 ± 2 and 5 ± 1 the number of 
peptides present in NAP9 and 
NAPSC respectively.  
Physical and chemical 
properties, including 
Zeta-potential, nanoparticle size 
(calculated as hydrated diame-
ter with dynamic laser light 
scattering (DSL, Malvern 
Zetasizer)), nanoparticle mor-
phology (visualized with 
transmission electron micros-
copy (TEM)), longitudinal and 
transverse relaxivities, were 
calculated. Longitudinal relax-
ivities were evaluated by using 
inversion recovery sequences 
with 15 inversion times. Trans-
verse relaxivities were calculat-
ed from spin-echo images and 
different echo times. In both 
cases, a series of images with 
 
Figure 1. Structure and chemical properties of NAP9 and NAPSC. A. Aminoacid composition of AP9 and AP9 
scrambled peptides. B. Composition of NAP9 and NAPSC micelles containing AP9 and AP9 scrambled peptides 
respectively. C. Structure of micelle components and conjugation of Cys-peptides to maleimide moiety. D. Physical and 
chemical properties of NAP9, NAPSC, and empty micelles. 
 




different T1 and T2 weighting were generated. The r1 
and r2 values were estimated from the slope of lon-
gitudinal and transverse relaxation rates vs Gd-DTPA 
or nanoparticle 8,9,10.  
Affinity measurements 
AP-9 peptide was labeled with Fluorescein 
isothiocyanate (FITC) (FluoroTAG-Conjugated KIT 
(Sigma-Aldrich)), according to the manufacturer´s 
instructions. FITC-labeled AP-9 (FAP-9) peptide and 
NAP9 micelles were used to examine affinity to en-
dogenous EMMPRIN in cardiac myocytes. 105 ad-
herent HL1 cells were plated into microwell plates 
and incubated with different concentrations ((10−7 M– 
10−12 M) of FAP-9 or NAP9 for 5 hours at 37 °C. 
Binding experiments were performed in the absence 
or presence of a 100-fold excess AP-9 non-labelled 
peptide for competition assays. Specificity was tested 
by incubation FAP-9 or NAP-9 with 100 µM specific 
anti-EMMPRIN antibody. At the end of incubation, 
the cells were resuspended, then pelleted down, and 
fluorescence was measured in the supernatant (free 
peptide or micelle), and in the pellet (peptide or mi-
celle bound to endogenous EMMPRIN) fractions. Kd 
values were calculated with GraphPad Prism soft-
ware.  
Cardiac Magnetic Resonance (CMR) 
All magnetic resonance imaging (MRI) experi-
ments were performed on a Bruker Biospec 47/40 
(Bruker Biospin, Ettlingen, Germany) operating at 4.7 
Tesla equipped with a 6 cm gradient system capable 
of reaching a maximal gradient strength of 450 mT/m. 
Animals were anesthetized with a mixture of 
isoflurane and oxygen and then placed in prone posi-
tion inside a 3.5 cm birdcage coil (Bruker Biospin, 
Ettlingen, Germany). Image acquisition was gated to 
the ECG and respiration signals using an external 
monitoring and gating system (SAII, New York, 
USA). 
To localize the short axis image planes, two and 
four chambers images were acquired along the entire 
heart of the mouse. For these images an ECG and 
respiration-gated gradient echo images were used. 
The parameter for these experiments were: Repetition 
Time (TR) = 15 ms; Echo Time (TE) = 2.5 ms; Number 
of averaged experiments (NEX) = 2; Field of view 
(FOV) = 3 x 3 cm2; Slice Thickness (SLTH) = 1.0 mm; 
Acquired Matrix = 128 x 128. 
Cardiac and respiratory triggered gradient echo 
images on the selected planes were acquired before 
and after the contrast agent injection. The measure-
ments after injection were repeated every 15, 30, 60, 
and 120 minutes and in some cases 24 hours after the 
injection. The images on each plane were acquired 
separately. The parameters for these experiments 
were: TR = 200 ms; TE = 2.3 ms; flip angle = 80o; NEX 
= 8; matrix = 128 x 128; FOV = 2.5 x 2.5 cm2; SLTH = 
1.0 mm. 
Image analysis: For in vivo MR images, the sig-
nal-to-noise ratio (SNR) of the region of interest (ROI) 
is defined by SNRROI= IROI/Inoise where IROI is the in-
tensity of either left ventricle of interest (for SNRlv) or 
surrounding muscle (for SNRm); Inoise is the standard 
deviation (S.D.) outside the animal. The normalized 
enhancement ratio of left ventricle (NERlv) to muscle 
is defined as:  
 
 
SNR=Signal to noise ratio= Mean signal intensity/SD. 
Eight MR images of the matched (pre- and 
post-contrast) slices for each mouse were used for 
analysis. 
Statistical analysis  
Unless otherwise specified, data are expressed as 
means ± SD. Cell culture experiments were performed 
in triplicate, and conditions were assayed in duplicate 
on each replicate. Animal experiments were per-
formed in triplicate, and the numbers of animals and 
replicates are specified in the text. Whenever com-
parisons were made with a common control, signifi-
cance of differences was tested by analysis of variance 
followed by Dunnett's modification of the T test. Dif-
ferences were considered significant at p<0.05. Error 
bars represent ± SD. 
Results 
NAP9 nanoparticle binds to EMMPRIN in vitro 
and in vivo 
Targeted micelles were generated by adding a 
cysteine residue at the N-terminus of EMMPRIN 
binding peptide AP-9 (NAP9), and linked to the ma-
leimide moiety of the micelles. Control micelles were 
generated by adding a cysteine residue to an AP-9 
scrambled peptide and conjugated as before (NAPSC) 
(Fig. 1A, B, and C). Physical and chemical properties 
of the micelles are shown (Fig 1D).  
Affinity of AP-9 peptide and NAP9 micelles to 
endogenous EMMPRIN were calculated in HL1 my-
ocytes (see methods for details) showing predicted 
binding affinities Kd=8 ± 0.6 nM, and Kd=6 ± 0.9 nM 
respectively. In the same way, nanoprobe cytotoxicity 
was tested in HL1 myocyte cell cultures 48 hours after 
incubation with increasing amounts of NAP9, and the 
percentages of living, necrotic, and apoptotic cells 




were determined by flow cytometry (Fig. 2A). We 
selected a concentration of 10 nM NAP9 as the max-
imal nanoparticle concentration with no significant 
effect on cell viability (Fig. 2A), and visualized by 
confocal microscopy (Cy3, red, Fig 2B). 
Co-localization of micelles with endogenous 
EMMPRIN (FYCT, green, Fig. 2B) was restricted to 
NAP9 positive cells (Merged, co-localization in yel-
low. Fig. 2B). 
In vivo toxicity of NAP9 was assayed in healthy 
mice 10 days after IV administration of 1, 10, 50 and 
100 mg/kg NAP9, by measuring serum levels of as-
partate transaminase (AST) and alanine transaminase 
(ALT), as markers of liver performance, creatinine, an 
indicator of kidney functionality, and creatinine ki-
nase-MB, indicative of cardiac necrosis, showing no 
significant signs of liver, kidney or heart muscle tox-
icity (Fig. 3A). In addition, NAP9 biodistribution was 
tested by confocal microscopy in the heart, liver, kid-
ney, pancreas, spleen, lungs and bladder of 50 mg/Kg 
NAP9 injected mice 24 hours after IR, showing the 
higher uptake of NAP9 in the hearts and lungs of 
these mice (Fig. 3B, left). It may be that the levels of 
NAP9 present in the lungs respond to a significant 
accumulation of micelles trapped in the pulmonary 
microvasculature. Nevertheless, no aggregates were 
visualized; rather a strong co-localization of NAP9 
with endogenous EMMPRIN in the pulmonary alve-
oli was detected by confocal microscopy (Fig. 3B, 
right).  
NAP9 uptake into mouse hearts is increased in 
response to IR  
Mice were subjected to IR and injected with 1, 10, 
50, or 100 mg/kg NAP9, NAPSC or saline (Control) 
and 24 hours after IR, cardiac parameters were eval-
uated by cardiac ultrasound; the animals were then 
sacrificed for further analysis (Fig. 4A). 
NAP9 uptake was detected by confocal micros-
copy in the hearts of healthy mice, and in mice sub-
jected to IR. A dosage of 50mg/kg NAP9 was selected 
as the amount of NAP9 visualized by confocal mi-
croscopy with lower toxicity (Figs. 3A, and 4B).  
The expression of endogenous EMMPRIN was 
stimulated in cardiac cells as a result of IR, as expected 
(Fig. 4B, Control lower panel), and NAP9 but not 
NAPSC co-localized with endogenous EMMPRIN in 
the heart (NAP9 and NAPSC lower panels, yellow). 
 
 
Figure 2. NAP9 binds to EMMPRIN in HL1 myocyte cells. A. Percentage of healthy, necrotic, and apoptotic HL1 myocytes incubated with NAP9 at the dosages shown. B. 
Confocal microscopy visualization of NAP9, NAPSC, and EMMPRIN in HL1 myocytes. Cells were incubated 1 hour with 10nM NAP9 or NAPSC. Nanoprobe uptake was 
evaluated by detection of Rhodamine (NAP9, and NAPSC, red). Endogenous EMMPRIN was detected in green (anti-EMMPRIN primary antibodies and FITC-conjugated 
secondary antibodies (green)), Co-localization was detected by merging both fluorescing signals (Merged panels, yellow). Scale bars, 50 μm (n= 3 by triplicate). 





Figure 3. In vivo toxicity of NAP9. A. Mice were injected with NAP9 at the dosages shown. After 10 days, plasma levels of hepatic alanine transaminase (ALT), aspartate 
transaminase (AST), creatinine (Crea) and creatinine kinase (CK-MB) were measured. (n=9 mice). B. Tissue distribution of 50 mg/Kg NAP9 in the same mice as before, as 
detected by confocal microscopy. Right. Confocal microscopy visualization of endogenous EMMPRIN (green) and NAP9 (red) in crossed sections of pulmonary tissue. Merged 
plane shows co-localization of both signals in yellow.  
 
The uptake of NAP9 was maximal in the heart 
sections of mice subjected to IR, when compared to 
the hearts of healthy mice, or with mice subjected to 
IR and injected with 50 mg/Kg NAPSC (Fig. 4B lower 
panel, NAP9).  
Double immunostaining of heart sections of mice 
subjected to IR with Rhodamine and anti-MHC anti-
body, or with rhodamine and anti-CD68 antibody 
shows specificity of NAP9 uptake by cardiac myo-
cytes and infiltrated macrophages (Fig. 4C). 
NAP9 induces cardiac protection in mice sub-
jected to IR 
IV injection of 50 mg/kg NAP9 into mice sub-
jected to IR improved heart contractility (Fig. 5A. 
LVEF: NAP9 63% ± 7.24 vs Control 42% ± 4.74 or 
NAPSC 39% ± 6.44 respectively), and reduced cardiac 
necrosis (Fig. 5B, Infarct size: NAP9 32%±6.59 vs 
Control 46%±9.04 or NAPSC 48%±7.64), when com-
pared to mice injected with NAPSC or saline (Control) 
under the same conditions. Table 1 lists the cardiac 
parameters collected after M-mode ultrasound evalu-
ation of mice. 
We previously found that IR induces the expres-
sion of EMMPRIN in mouse hearts7, leading to the 
expression and activity of different MMPs, including 
gelatinases A and B (MMP-2, and 9 respectively), two 
crucial ECM-degrading enzymes of heart tissue in 
response to ischemic conditions. To further illustrate 
the contribution of NAP9 in the survival of cardiac 
myocytes, we analyzed the levels of MMP-2, and 
MMP-9, indicative of EMMPRIN activation in the 
heart. We found that in mice injected with 50 mg/Kg 
NAP9, the levels of MMP-2 and MMP-9 were almost 
reduced to those found in healthy animals (Fig 5B, 
and C). Taken together, these results show that NAP9 
improves heart contractility at least in part by target-
ing EMMPRIN thorough the AP9-conjugated peptide, 
since empty micelles (Fig. 5B, Control micelles) or 
micelles containing AP-9 scrambled peptides (Fig. 5B, 
NAPSC micelles) did not reduce the levels of MMP-2 
and MMP-9, nor did they improve heart contractility. 




Table 1. Cardiac function. 
 Healthy Control (Saline) NAP9 NAPSC 
LVDS (mm) 2.752±0.49 3.593±0.65 3.012±0.53 3.415±0.69 
LVDD (mm) 4.201±0.21 4.551±0.51 4.302±0.37 4.617±0.49 
VS (ml) 25.271±2.88 52.953±7.03 * 32.217±4.11 50.216±7.06 § 
VD (ml) 66.408±10.46 79.355±11.52 72.396±6.14 81.046±9.32 
SV (ml) 41.137±3.2 26.402±1.25 40.179±5.61 30.83±5.22 
EF (%) 61.946±4.38 33.271±5.92 * 55.499±4.25 38.04±4.32 § 
FS (%) 34.497±2.95 21.05±2.45 29.986±4.74 26.034±1.89 
Heart rate (bpm) 389±12 388±12 402±11 395±17 
LVDS, left-ventricle end-systolic diameter; LVDD, left-ventricle end-diastolic diameter; VS, systolic volume; VD, diastolic volume; SV, systole–diastole volume difference; 
EF, left-ventricle ejection fraction; FS, shortening fraction.  
*p<0.05 Healthy vs Control. §p<0.05 Healthy vs NAPSC. 
 
 
 Figure 4. NAP9 binds to EMMPRIN in mouse hearts subjected to IR. A. Study design. B. Confocal microscopy visualization of NAP9, or NAPSC (rhodamine, red), and 
endogenous EMMPRIN (FITC, green) in healthy hearts (upper panels) and in hearts subjected to IR (lower panels). Scale bars: 50 μm (n=9 mice/condition). C. Confocal 
microscopy visualization of NAP9 (rhodamine, red) and the macrophage marker CD68 (FlTC, green) or the muscle cell myosin heavy chain (MHC, FITC, green) in hearts 
subjected to IR (n=9 mice).  





Figure 5. NAP9 induces cardiac protection in mice subjected to IR. A. LVEF values from non ischemic (healthy) mice and from mice who underwent IR for 24 hours 
and were injected with 50 mg/Kg NAP9, NAPSC, or saline (Control) right after ischemia (n=9 mice/group. Mean ± SD; *p <0.05, NAP9 vs Control). B. Measurement of LV 
necrotic area as percentage with respect to the area at risk, detected by double Evans Blue/TTC staining (n = 18 mice/group; mean ± SD; *p <0.05, NAP9 vs Control). C. 
Immunoblot detection of MMP9 (upper panel), and MMP-2 (lower panel) in non ischemic (Healthy) mice, and in mice injected with 50 mg/Kg NAP9, NAPSC, or saline (Control) 
right after reperfusion. GAPDH was used as loading control (n=9 mice/group; mean ± SD; *p <0.05, NAP9 vs Control and NAPSC). D. Detection of MMP-9 by Gelatin 
zymography in the same hearts as in C. The two bands of 92 kDa and 87kDa correspond with the sizes of proMMP-9 and active-MMP-9 respectively. LMW: low molecular weight. 
HMG: high molecular weight (n=9 mice/group; mean ± SD; *p <0.05, NAP9 vs Control and NAPSC). 
 
Non invasive Magnetic Resonance Imaging of 
NAP9 correlates with ex vivo LV infarction 
size  
To test whether NAP9 could have a theranostic 
effect, we performed CMR scans in healthy mice or in 
mice subjected to IR, and injected with 50 mg/Kg 
NAP9, NAPSC, or saline (Control) (Fig. 6A). In 
healthy animals, neither NAP9 nor NAPSC caused 
enhancement of the hearts at 24 hours post injection 
(Fig. 6B upper panels). By contrast, in mice under IR, 
injection of NAP9 caused a significant enhancement 
of the heart when compared to Control and NAPSC 
injected animals (Fig. 6B. Right. Graphical represen-
tation corresponding to 3 independent experiments 
showing normalized enhancement ratios: Control IR 
2.24 ± 4.86, NAPSC IR 6.96 ± 2.93%, NAP9 IR 24.39 ± 
7.22%).  




The same mice were used to evaluate ex vivo 
cardiac damage by Evans Blue/TTC staining, detect-
ing a positive correlation between NAP9 uptake, as 
detected by CMR, with ex vivo measurement of in-




Figure 6. Non invasive CMR visualization of NAP9 in mice subjected to IR, correlates with ex vivo Evans Blue/TTC measures taken in the same mice. A. 
CMR study design. B. Parasternal short axis view of hearts from healthy mice (upper), or mice who underwent IR for 24 hours (IR, lower), and were injected with 50 mg/Kg 
NAP9, NAPSC, or saline (Control). Bottom. Detailed magnification of NAP9-injected healthy mice, or mice under IR. Green lines show Gadolinium enhanced areas corre-
sponding to nanoprobe uptake. Blue and red dotted lines are marking external and internal LV walls respectively. Right graph shows the result of 3 independent assays (n=9 
mice/condition; mean ± SD; *p <0.05, NAP9 vs Control and NAPSC in AMI). C. Scattered plot representing the extension of NAP9 uptake as detected by CMR (Y axis) with 
respect to the extension of infarct size, estimated by Evans Blue/TTC staining (X-axis) (R=0.69; p<0.05). 
 





Figure 7. NAP9 has no effect before IR. A. Study design. B. LVEF of healthy hearts or hearts from mice subjected to IR and injected one day before (Group A: T-1d) at the 
same time (Group B: T0d) or one day after (Group C: T+1d) with 50 mg/Kg NAP9, NAPSC, or saline (Control), and measured 24 hours after injection (see schematic rep-
resentation of the assay) (n=10 mice/condition; mean ± SD; *p <0.05, NAP9 t0 vs NAP9 t-1d; p <0.05, NAP9 t+1d vs NAP9 t-1d). B Immunoblot detection of MMP-9 in the same 
hearts as before. GADP was used as loading control (n=9 mice/group *p <0.05, NAP9 vs Control).  
 
The cardioprotective effect of NAP9 is maxi-
mal within the first 24 hours after injection  
We found that NAP9 induces cardiac protection 
in mouse hearts subjected to IR. To determine the best 
time for nanoprobe administration, mice were inject-
ed with 50mg/kg NAP9, or NAPSC, 1 day before IR 
(t-1d, group A), at the time of ischemia (t0d, group B), 
and 1 day after IR (t+1d, group C) (Fig. 7A), and ven-
tricular function (Fig. 7B), and MMP-9 expression (Fig 
7C) were analyzed 24 hours after the procedures. The 
cardioprotective effect of NAP9 was maximal in mice 
injected with NAP9 at the time of ischemia (t0) and 
one day after (t1) IR, with respect to control mice and 
to mice injected with 50 mg/Kg NAPSC and subjected 
to IR (Fig. 7B,C). By contrast, administration of NAP9 
before ischemia (t-1) had a non significant effect on 
LVEF (Fig. 7B), and MMP-9 expression (Fig. 7C). 
Mice were subjected to IR and injected 24 hours 
later with 50 mg/Kg NAP9 or NAPSC, and CMR 




scans were performed at different times after injection 
(Fig. 8A). NAP9 was visualized within the first 30 
minutes and the signal was enhanced within the next 
two hours post injection (Fig. 8B). Taken together, 
these results suggest that NAP9 might be used to in-
hibit and to quantify the extension of myocardial cell 
death during the onset and progression of AMI by 
targeting EMMPIN in vivo. 
Discussion 
Extracellular matrix degradation is a key step 
that precedes cardiac remodeling as a result of coro-
nary artery occlusion, and subsequent ischemia and 
reperfusion12. In the current study, we found that 
targeting extracellular matrix metalloproteinase in-
ducer (EMMPRIN) with paramagnetic fluorescent 
micellar nanoparticles successfully reduced reperfu-
sion damage in hearts subjected to AMI. Likewise, 
extracellular matrix degradation as detected by ex-
pression of matrix metalloproteinase MMP-9 was no-
tably reduced in mice injected with NAP9, when 
compared with NAPSC, containing an AP scrambled 
peptide. CMR scans in mice subjected to IR revealed a 
signal enhancement after injection with NAP9, 
whereas scans in mice injected with nanoparticles 
conjugated with AP9 scrambled peptide (NAPSC) did 
not show differences with respect to Control mice. 
Confocal microscopy detection of NAP9 in the same 
hearts confirmed the result, and in addition, NAP9 
co-localized with endogenous EMMPRIN. A positive 
correlation between infarct size and CMR signal en-
hancement was also identified, which may suggest 
that future consideration should be given to this 
technology for fast, non-invasive detection and heart 
performance improvement in humans subjected to 
AMI.  
 
Figure 8. NAP9 is detected in mouse hearts within the first 30 minutes of injection. A. Study design and timeline of imaging assessments. B. Parasternal shot axis 
view of mouse hearts at the times indicated after injection of 50mg/Kg NAP9 or NAPSC. White arrows point to gadolinium areas of enhancement. Bottom left: Normalized 
enhancement ratios. (n=9 mice/condition. mean ± SD; *p <0.05, NAP9 vs No lipid and NAPSC). Bottom right, magnification of CMR images recorded 120 minutes after injection. 
The area of signal enhancement is represented in red. 




Targeting of EMMPRIN was investigated as a 
therapeutic mechanism against numerous pathologies 
including several types of cancer, and kidney, liver, 
lung, and pancreatic diseases 13-19. The involvement of 
EMMPRIN in cardiovascular diseases was also evi-
denced 20. In atherosclerosis, induction of EMMPRIN 
by monocyte and proinflammatory macrophages 
plays a pivotal role in foam cell and plaque formation 
21, smooth muscle cell proliferation and migration 22, 
and platelet activation; it significantly contributes to 
plaque burden, as well 23. In the heart, infiltrated 
monocytes and cardiac myocytes produce large 
amounts of EMMPRIN in response to ischemia, pro-
moting MMP-mediated extracellular matrix degrada-
tion and cardiac cell death 24-26. In this regard, we 
found that antibody-mediated EMMPRIN inhibition 
reduced infarct size in murine models of IR 7.  
Paramagnetic micelles have been used to target 
cells 27 and molecules 28 in the onset and progression 
of several diseases, by coupling different molecules to 
target the desired cell type, enzyme, binding protein 
or, very recently, pathophysiological conditions like 
apoptosis, angiogenesis, or even ischemia29-31. We 
targeted EMMPRIN by using gadolinium 
based-paramagnetic micelles containing specifically 
EMMPRIN binding peptides for non-invasive visual-
ization of EMMPRIN by molecular MRI. 
The use of antibody-mediated targeting of pro-
teins has been successfully evaluated in animal mod-
els of disease 32. However, such an immunological 
approach was only effective in very few studies in 
humans, and therefore the translation to the clinic is 
limited for reasons that include immune cross reac-
tivity, antibody-mediated side effects, or lack of de-
sired therapeutic improvement. To avoid undesired 
immune reactivity, an efficient alternative is the use of 
smaller binding molecules to the target of interest, 
including specific binding peptides 15, 33. To our 
knowledge, the use of specific EMMPRIN-binding 
peptides has only been tested in vitro to inhibit 
EMMPRIN downstream MMP activation in 293 cells 
34, in monocyte THP-1 cells 35, and in peripheral blood 
monocytes isolated from patients with rheumatoid 
arthritis 36. We found, for the first time, that para-
magnetic nanoparticles conjugated with AP9 peptides 
bind to EMMPRIN as detected by confocal micros-
copy, and in vivo by molecular CMR. In addition, 
administration of NAP9 reduces downstream expres-
sion of MMP-2 and MMP-9 in the heart, and improves 
cardiac contraction when compared to AP9-scrambled 
conjugated nanoparticles. Nevertheless, a future 
translation to the bed side will require additional na-
noparticle formulation to avoid potential nanoparti-
cle-derived side effects. 
A close correlation between the CMR signal en-
hancement and myocardial infarction was calculated 
in NAP9 injected mice subjected to IR. However, 
NAP9 had no effect when administered 1 day before 
IR, whereas upon administration at the time of and 
one day after IR, NAP9 improved LVEF and reduced 
MMP-9 expression, which may be explained due to 
reduced expression of EMMPRIN in healthy hearts. 
In conclusion, NAP9 nanotherapy was shown to 
be effective to improve performance of hearts sub-
jected to IR, restoring functional parameters and pre-
venting MMP-mediated ECM degradation. Conse-
quently, further studies in other species will be crucial 
for future testing in humans. 
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